drugset / Trial / NCT02362516
Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the exposure of BI 425809 in cerebrospinal fluid relative to plasma as well as safety and tolerability, and to evaluate the effect of different doses of BI 425809 on biomarkers levels in cerebrospinal fluid.
Timeline
- Start
- 2015-02-23
- Primary completion
- 2015-06-19
- Completion
- 2015-06-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iclepertin | Small molecule | 5 mg | Oral |
| Subject | Iclepertin | Small molecule | 10 mg | Oral |
| Subject | Iclepertin | Small molecule | 25 mg | Oral |
| Subject | Iclepertin | Small molecule | 50 mg | Oral |
Indications
No indication recorded.